Virus News and Research

Latest Virus News and Research

Novavax announces final safety, immunogenicity results from H1N1 VLP vaccine at WHO meeting

Novavax, a clinical-stage biopharmaceutical company, today presented the final safety and immunogenicity results from its 2009 H1N1 virus-like particle pandemic influenza vaccine clinical trial in Mexico at the invitation-only 7th World Health Organization Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials.

19 Feb 2011

U.S. scientists assess progress of dengue vaccine at 3-day summit in Puerto Rico

During a meeting in Puerto Rico on Thursday to discuss recent progress towards fighting dengue, researchers voiced optimism over advances in the development of vaccines to prevent the spread of the virus, "which kills 25,000 people every year," Agence France-Presse reports. The three-day summit was hosted by the NIH, CDC and PAHO, according to the news service.

19 Feb 2011

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started.

18 Feb 2011

U.N.-backed meeting in Bangkok will examine how legal barriers in Asia hamper fight against HIV/AIDS

"Legal barriers are obstructing the fight against HIV/AIDS in the Asia, where 19 nations outlaw same-sex relations and 29 countries criminalize prostitution, United Nations experts said Wednesday," on the eve of the Global Commission of HIV and the Law meeting in Bangkok, Deutsche Presse-Agentur/M&C reports.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Experts say signs and treatment of bacterial infection often misunderstood

According to the Canadian Foundation for Infectious Diseases, antibiotics are the second most frequently prescribed class of drugs - second only to pain relievers. Yet most people don't know the difference between a true bacterial infection, like chronic bronchitis that can be treated with antibiotics — and viruses like the common cold, which cannot.

17 Feb 2011

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders. The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e., neurturin or NRTN, intended to restore and preserve dying neurons.

17 Feb 2011

New fully human monoclonal antibodies to battle Chikungunya

The Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and VIVALIS, a French biopharmaceutical company, announced today the discovery of two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment.

16 Feb 2011

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Vical Incorporated announced today the issuance of U.S. Patent No. 7,888,112 covering DNA vaccines for cytomegalovirus containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant.

16 Feb 2011

Flu vaccine update

This new vaccine which could become available in the United States in the next few years, is made by growing the influenza virus in cultures of animal cells rather than in the chicken eggs that have been used for more than five decades. This shortens the process by six months. Using animal cells, which are grown in enclosed steel tanks, also reduces the risk of bacterial contamination, which has led to shortages of seasonal vaccines in some years. The study was reported in The Lancet this Tuesday.

16 Feb 2011

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Baxter International Inc. announced today results of a study published in this week's issue of The Lancet that demonstrate effectiveness and tolerability of Baxter's PREFLUCEL in protecting against seasonal influenza.

From Baxter International Inc. 15 Feb 2011

Dengue strikes in a “vicious” way in north Qld

According to health authorities a vicious strain of Dengue fever is hospitalising people in far north Queensland. 20 people have been diagnosed with the Type 2 variant of the virus in East Innisfail and another five have Type 4 Dengue. 12 other people are possibly ill with the virus and awaiting laboratory confirmation.

15 Feb 2011

ITM research provides deep insight into interactions between HIV virus and human cells

Over the years, the AIDS virus has increasingly adapted itself to humans. This is shown by the research of Youssef Gali at the Institute of Tropical Medicine.

15 Feb 2011

Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters

Idera Pharmaceuticals, Inc. announced today that it is presenting data on IMO-3100, an antagonist of TLR7 and TLR9, in a preclinical model of lupus showing that treatment with IMO-3100 suppressed several key disease progression parameters.

15 Feb 2011

February is again peak time for influenza across the nation

If you thought the regular seasonal flu has been late making its annual appearance, you might be surprised to learn that based on recent history, it's right on time.

15 Feb 2011

TFAH applauds overall increase in disease prevention funding, expresses concern over CDC cuts

The Trust for America's Health (TFAH) applauds the President's budget for an overall increase in disease prevention funding, reflecting the new funds provided by the Prevention Fund from the Affordable Care Act (ACA), but expresses extreme concerns over the cuts to funding for core programs at the U.S. Centers for Disease Control and Prevention (CDC) and for emergency preparedness.

15 Feb 2011

Green on satellite images warns of hantavirus outbreaks

The risk of deadly hantavirus outbreaks in people can be predicted months ahead of time by using satellite images to monitor surges in vegetation that boost mouse populations, a University of Utah study says. The method also might forecast outbreaks of other rodent-borne illnesses worldwide.

15 Feb 2011

NIH awards renewal grant to BMC's CARE unit to expand education of physicians-in-training

The Clinical Addiction Research and Education Unit in the Section of General Internal Medicine at BMC was recently awarded a $1,886,087 renewal grant from the National Institutes of Health to expand its education of physicians-in-training to become sophisticated implementers of substance use screening, assessment and treatment research.

14 Feb 2011

Chimerix announces completion of $45 million Series F financing

Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.

14 Feb 2011

Novel technology to diagnose Alzheimer's disease before symptoms appear

UT Southwestern Medical Center scientists have helped develop a novel technology to diagnose Alzheimer's disease from blood samples long before symptoms appear.

14 Feb 2011

Virus News and Research

Latest Virus News and Research

Novavax announces final safety, immunogenicity results from H1N1 VLP vaccine at WHO meeting

U.S. scientists assess progress of dengue vaccine at 3-day summit in Puerto Rico

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

U.N.-backed meeting in Bangkok will examine how legal barriers in Asia hamper fight against HIV/AIDS

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Experts say signs and treatment of bacterial infection often misunderstood

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

New fully human monoclonal antibodies to battle Chikungunya

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Flu vaccine update

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Dengue strikes in a “vicious” way in north Qld

ITM research provides deep insight into interactions between HIV virus and human cells

Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters

February is again peak time for influenza across the nation

TFAH applauds overall increase in disease prevention funding, expresses concern over CDC cuts

Green on satellite images warns of hantavirus outbreaks

NIH awards renewal grant to BMC's CARE unit to expand education of physicians-in-training

Chimerix announces completion of $45 million Series F financing

Novel technology to diagnose Alzheimer's disease before symptoms appear

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in